Beta Bionics (BBNX) Stock Price, News & Analysis

Company Overview

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Key Stats

• Today's Range: $11.38 to $12.37
• 50-Day Range: $9.71 to $20.98
• 52-Week Range: $8.89 to $24.50
• Volume: 419,801 shs
• Average Volume: 474,227 shs
• Market Capitalization: $512.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.83
• Consensus Rating: Moderate Buy

BBNX Stock Analysis - Frequently Asked Questions

How have BBNX shares performed this year?

Beta Bionics' stock was trading at $23.81 at the start of the year. Since then, BBNX shares have decreased by 50.3% and is now trading at $11.83.
View the best growth stocks for 2025 here.

How were Beta Bionics' earnings last quarter?

Beta Bionics, Inc. (NASDAQ:BBNX) issued its earnings results on Tuesday, March, 25th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $1.40. The firm earned $20.44 million during the quarter, compared to analyst estimates of $20.01 million.
Read the conference call transcript.

When did Beta Bionics IPO?

Beta Bionics (BBNX) raised $204 million in an initial public offering on Thursday, January 30th 2025. The company issued 12,000,000 shares at $17.00 per share.

When does the company's lock-up period expire?

Beta Bionics' lock-up period expires on Tuesday, July 29th. Beta Bionics had issued 12,000,000 shares in its IPO on January 30th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Who are Beta Bionics' major shareholders?

Beta Bionics' top institutional investors include Evanson Asset Management LLC (0.09%), Values First Advisors Inc. (0.09%), Bank of New York Mellon Corp (0.06%) and Rhumbline Advisers (0.03%). Insiders that own company stock include Hadley Harbor Aggre Wellington and Mike Mensinger.
View institutional ownership trends.

How do I buy shares of Beta Bionics?

Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/25/2025
• Today: 5/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBNX
• Previous Symbol: NASDAQ:BBNX
• CIK: 1674632
• Web: N/A
• Phone: (949) 427-7785
• Fax: N/A
• Employees: 294
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.83
• High Stock Price Target: $30.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +109.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $65.12 million
• Price / Sales: 7.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 43,349,000
• Free Float: N/A
• Market Cap: $512.82 million
• Optionable: N/A
• Beta: N/A